RESCUE-RESS
(2025)Objective
To evaluate whether XingNaoJing (XNJ), a traditional Chinese herbal neuroprotectant, improves outcomes in acute ischemic stroke patients after EVT
Study Summary
• Phase 3 trial of XingNaoJing (herbal cytoprotectant) vs best medical care post-EVT
• 424 patients enrolled; 95.75% achieved successful reperfusion (TICI 2b-3)
• Results pending — baseline data only presented
• 424 patients enrolled; 95.75% achieved successful reperfusion (TICI 2b-3)
• Results pending — baseline data only presented
Intervention
XingNaoJing 20 mL IV q12h for 10 days vs best medical treatment
Inclusion Criteria
Acute ischemic stroke, EVT within 24 hours, randomization within 24 hours of EVT
Study Design
Arms: XingNaoJing + standard care vs Standard care alone
Patients per Arm: 424 total, 1:1 randomization (arm breakdown not specified)
Outcome
• Primary: mRS 0–2 at 90 days — RESULTS PENDING
• Secondary: Neurological deterioration, sICH, final infarct volume, NIHSS change at day 14, recurrent stroke, death, composite vascular events at day 90 — RESULTS PENDING
• Secondary: Neurological deterioration, sICH, final infarct volume, NIHSS change at day 14, recurrent stroke, death, composite vascular events at day 90 — RESULTS PENDING